Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci143 in Advanced Solid Tumors
NCT07252414Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Cytotoxic ADCs
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of GenSci143 in solid tumor and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Incidence of adverse events, Dose limiting toxicities at 21 days and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
GenSci143
03
Conditions
solid tumormetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07252414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252414.